Atinumab Biosimilar – Anti-RTN4, NOGO mAb – Research Grade

Description of Atinumab Biosimilar - Anti-RTN4, NOGO mAb - Research Grade

Introduction

Atinumab Biosimilar, also known as Anti-RTN4, is a monoclonal antibody (mAb) that targets the protein RTN4, also known as NOGO. This protein is involved in the inhibition of nerve regeneration and has been identified as a potential therapeutic target for various neurological disorders. Atinumab Biosimilar is a research grade antibody that has shown promising results in preclinical studies and is currently being evaluated for its potential therapeutic applications.

Structure of Atinumab Biosimilar

Atinumab Biosimilar is a recombinant humanized IgG1 monoclonal antibody, meaning that it is derived from human antibody sequences and has been modified to have a longer half-life in the body. It is composed of two heavy chains and two light chains, with a total molecular weight of approximately 150 kDa. The antibody has a Y-shaped structure, with two antigen-binding sites at the ends of the Y, allowing it to bind to its target with high specificity and affinity.

Activity of Atinumab Biosimilar

The primary function of Atinumab Biosimilar is to bind to RTN4 and block its activity. RTN4 is a protein that is predominantly expressed in the central nervous system and has been found to inhibit the regeneration of nerve cells. By binding to RTN4, Atinumab Biosimilar prevents it from interacting with its receptors on nerve cells, thereby promoting nerve regeneration.

In addition to its inhibitory effect on nerve regeneration, RTN4 has also been implicated in other processes such as cell migration and axonal guidance. Atinumab Biosimilar has been shown to modulate these processes as well, providing a potential mechanism for its therapeutic effects in neurological disorders.

Application of Atinumab Biosimilar

Atinumab Biosimilar is currently being studied for its potential therapeutic applications in neurological disorders such as spinal cord injury, stroke, and multiple sclerosis. These conditions are characterized by damage to nerve cells and impaired nerve regeneration, making RTN4 a relevant therapeutic target.

In preclinical studies, Atinumab Biosimilar has shown promising results in promoting nerve regeneration and improving functional outcomes in animal models of spinal cord injury and stroke. It has also been shown to reduce inflammation and demyelination in models of multiple sclerosis, suggesting a potential role in the treatment of this autoimmune disorder.

Conclusion

In summary, Atinumab Biosimilar is a research grade monoclonal antibody that targets the protein RTN4, or NOGO, which is involved in the inhibition of nerve regeneration. With its specific and potent activity, Atinumab Biosimilar has shown potential in promoting nerve regeneration and modulating other processes involved in neurological disorders. Further clinical studies are needed to fully evaluate its therapeutic potential and bring this promising antibody to patients in need.